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384patients have impaired underlying left ventricular function (poor ejec-
tion fraction). This study was performed to compare the effect of postop-
erative oral carvedilol versus metoprolol on left ventricular ejection
fraction (LVEF) after CABG compared with metoprolol. In a double-
blind clinical trial, 60 patients with coronary artery disease, aged 35 to
65 years, who had an ejection fraction of 15% to 35% were included.
Either carvedilol or metoprolol was administered the day after CABG.
The patients were evaluated by the same cardiologist 14 days before
and 2 and 6 months after elective CABG. The results demonstrated better
improvements in LVEF in the carvedilol group. No difference regarding
postoperative arrhythmias or mortality was detected. The results suggest
that carvedilol mayexertmore of an improvedmyocardial effect thanme-
toprolol for the low ejection fraction patients undergoing CABG in the
early postoperative months.
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CARVEDILOL VERSUS METOPROLOL AFTER CABG 385failure. This preexisting heart failure leads to in-
creased postoperative mortality and morbidity
and impaired quality of life.2,3
b-adrenergic blockers have been shown to decrease
the mortality and morbidity of heart failure pa-
tients.2-4 Carvedilol, a nonselective third-generation
adrenergic blocker, is more effective than other
b-adrenergic blocking agents, especially in patients
who have experienced myocardial infarction
(MI).3-7 This study was designed and performed to
compare the effect of postoperative oral carvedilol
versus oral metoprolol on increasing EF after CABG.
Materials and Methods
This research study received approval from the
Institutional Review Board Committee for Ethical
Considerations, Research Deputy, Shahid Beheshti
University of Medical Sciences, Tehran, Iran.
The research project was accomplished during
a 24-month period from January 2008 through
December 2009. Patients gave written informed
consent before enrollment in the study.
In a prospective randomized double-blind clinical
trial, 60 patients with coronary artery disease
were enrolled. The study included 22 women
and 38 men, whose ages ranged from 35 to 65
years and who had an EF of 15% to 35%. The EF
was confirmed by the same cardiologist during
echocardiography and angiography.
The patients also each had a history of recent MI.
The MI had occurred more than 4 weeks before
the study and was documented by electrocardio-
graphic (ECG) and dipyridamole-thallium imaging
results. Those patients who had a recent MI during
the last 4weekswere excluded because those who
have had a recent MI within 4 weeks are not usu-
ally considered appropriate candidates for elective
CABG. Viability of the myocardium was deter-
mined by single-photon emission computed to-
mography (SPECT) and stress echocardiography.
Those patients older than 65 or younger than
35 yearswere excluded from the study. Also, the fol-
lowing items were considered as exclusion criteria:
 urgent surgery
 history of recent MI during the last 4 weeks evidence of atrioventricular block or severe
sinoatrial node dysfunction, according to
the ECG assessments
 no viable myocardium
 any contraindications for administration of
b-blockers
The patients were assigned randomly into one of
two study groups using a computer table of ran-
dom numbers for random allocation. The first
group (group 1), which included 30 patients,
received oral carvedilol, and the second group
(group 2), also including 30 patients, received
oral metoprolol tartrate. Both groups received
the drugs after elective CABG.
All the patients underwent echocardiography dur-
ing 14 preoperative days before the surgical opera-
tion and again at 2 and 6 months after CABG.
The echocardiography examination was again
performed by the same cardiologist and echocardio-
graphicmachine (GE Vingmed Vivid 5 Echocardiog-
raphy System; All Imaging Systems, Inc., Irvine, CA)
in the same hospital. During the postoperative
period, the patients were evaluated regarding atrial
arrhythmias and 1-month mortality.
Conventional on-pump CABGwas performed in all
60 patients. After establishing cardiopulmonary
bypass, mild hypothermia (32C, passive cooling)
was used, with crystalloid cardioplegia solution.
The b-blocker drugs were begun the day after the
operation. Low-dose oral carvedilol (3.125 mg)
twice daily was started for the first group. If the
patient tolerated the drug, the dose was gradually
increased over 2 weeks to reach a maximum of
12.5 mg twice daily. Low-dose oral metoprolol tar-
trate (50 mg/day) was used for the second group
by the same pattern of administration. If the pa-
tient tolerated the drug, the dose was gradually
increased over 2 weeks to reach a maximum
of 200 mg twice daily to reach a maximum of
400 mg per day. These doses are comparing equi-
potent dosages of the two drugs. For both drugs,
the signs of intolerance that were critical markers
were intolerable fatigue, sinus bradycardia with
a heart rate of less than 45 per minute, and
shortness of breath. If any of these occurred with
drug administration, the drug would be discontin-
ued and the patient would be excluded from the
study. Fortunately, none of the patients had any
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These medications were controlled to prevent
their effect on the myocardial function: digoxin,
angiotensin-converting enzyme inhibitors, and
diuretics. No other variables with a possibility for
affecting the myocardial function were considered
necessary to be controlled and monitored. This is
a possible limitation of the study.
Statistical Analysis
The study data were recorded and extracted from
each patient’s data sheet. Statistical analysis was
performed using SPSS (version 11.5; SPSS Inc,
Chicago, IL). For statistical data analysis, Student
t test, chi-square test, and analysis of variance
were used. A value for P less than .05 was consid-
ered significant.
Results
The two groups had no statistically significant dif-
ference regarding age and the number of coronary
grafts in the operation (Table 1). There were no dif-
ferences between the twogroups regarding gender
or in the incidence of diabetes mellitus, hyperlipid-
emia, hypertension, previous history of MI, smok-
ing, and preoperative arrhythmias (P value for all
the variables greater than .05). The two groups
did not differ regarding their medications, includ-
ing digoxin, angiotensin-converting enzyme inhib-
itors, and diuretics.
The results also demonstrated that there was no
difference regarding lengths of surgery, pump
run, intensive care unit stay, and hospitalization be-
tween the two groups. All CABG operations were
performed by the same surgeon.Table 1. Distribution of Age and Graft
Numbers in the Study
Variables
Carvedilol
Group
Metoprolol
Group P Value
Age (y) 566 6.5 576 5.4 .33
Number of grafts 3.46 0.8 3.66 0.7 .8
Figures are demonstrated as mean 6 standard
deviation.Therewas only one death in the second group (me-
toprolol group), which occurred in the fifth post-
operative day after a cerebral vascular accident.
Both groups had increased performance of the left
ventricle as demonstrated in their EF of the left
ventricle (LVEF), 2 and 6 months after CABG,
when compared with their preoperative echocar-
diography assessments. In group 1 (ie, carvedilol),
EF was increased from baseline values to higher
ranges in the assessments performed at 2- and
6-month periods. In group 2 (ie, metoprolol), the
EF had a similar pattern. The improvements in
LVEF were significantly increased in group 1 (car-
vedilol group) compared with group 2 (metopro-
lol group) (Table 2). However, the two groups
had no significant difference regarding functional
status assessed by the New York Heart Association
classification, 6 months after the operation.
Although bradycardia was more common in the
carvedilol group (three patients versus one pa-
tient), the incidence of other arrhythmias (atrial
fibrillation [AF] or flutter, premature atrial beats,
or premature ventricular contractions) was not
significantly different. No difference may have
been secondary to low sample size.
Discussion
The study demonstrated an increase in LVEF in carve-
dilol group. The study suggests that carvedilol is
more effective in patients than metoprolol to in-
crease EF after CABG. EF may rise 5% to 10% after
CABG surgery, however, in this study, the assess-
ments performed after 6 months demonstrated that
the increase was greater than 10% in both groups.
The carvedilol group increased approximately
18%. Much of this increase occurred during the firstTable 2. Left Ventricle Performance
Assessment (Demonstrated as LVEF)
Variables
Carvedilol
Group
Metoprolol
Group P Value
Before the
operation
26.56 5.1 28.26 4.5 .33
2 mo after CABG 41.16 6.3 34.56 5.2 .02
6 mo after CABG 44.36 6.2 38.76 5.4 .02
LVEF, left ventricular ejection fraction; CABG, coro-
nary artery bypass graft.
Figures are demonstrated asmean6 standard deviation.
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during the next 4 months (Table 2).
In a 2005 study that looked at LVEF after CABG in
20 patients with chronic hibernated myocardium
studied before and after revascularization, the ef-
fect of carvedilol on hibernating myocardium was
significantly better than that of metoprolol. The
authors of the study described their finding related
‘‘partially’’ to the ‘‘reduced cardiomyocyte degener-
ation’’ after carvedilol administration.8 All our
patients had a history of previous MI that was evi-
denced by ECG, stress echocardiography, or SPECT,
but the patients in the above study had hibernating
myocardium that would be accompanied with
a better response to revascularization, and the
sample size was smaller than that in our study.
Carvedilol was demonstrated to produce better
effects on the performance of the LVEF than
metoprolol (with equal doses), especially when
prescribed long term.9 The difference in patient
mortality after metoprolol and carvedilol adminis-
tration is due to the greater counteradrenergic
properties of carvedilol. Both drugs are b-blocking
agents, but it is only carvedilol that is both a nonse-
lective b-blocker and also an a-1 blocker.10 To
strengthen these findings, other studies have as-
sessed the effects of carvedilol when used in thepostoperative period after landiolol administration.
Landiololwas not assessed in our study; but in other
studies, landiolol has demonstrated an enhanced
protective effect against tachycardia during AF in
post-CABG patients.11 Another study demonstrated
that in post-CABG patients, therapeutic landiolol in
‘‘low doses’’ can decrease the prevalence of AF.12
However, our study did not demonstrate any differ-
ence regarding the incidence or prevalence of
arrhythmias or postoperative 6-month mortality.
These issues differed from previous research, but
the results of this study could demonstrate the
effect of carvedilol on LVEF to be superior to
metoprolol, a therapeutic effect of the drug that
could be because of its effects as a counteradrener-
gic agent.9-12 Therefore, it would demonstrate this
effect as better performance on the poorly
functioning myocardium during the early post-
CABG months.
Conclusion
Carvedilol could improve LVEF in the early postop-
erative period after CABG. When compared with
metoprolol in patients with low EF, the patients
demonstrate better early postoperative perfor-
mance of left ventricle. Evaluating patients with
at least 1-year follow-up is recommended to assess
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